newest glp 1 agonist Upcoming wave of hormone-based therapies set to change field of diabetes, obesity care A schematic overview of GLP-1
Description
Finally, focused work on GI and hepatobiliary cancerswhere obesity and metabolic dysfunction are critical driverswill be essential to fully define the oncologic role of GLP-1RAs
The key difference is the magnitude of the result
1 spot for the first time
If ASC35s promising preclinical potency and extended half-life translate successfully to humans, it could mark a significant step forward in patient convenience and adherence a key differentiator in the competitive metabolic therapy landscape
Diabetes and Endocrinology 9653662
L.Tomaro-DuchesneauC.BrittonR
